BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20190331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20191027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200824
DTEND;VALUE=DATE:20200829
DTSTAMP:20260403T180936
CREATED:20200214T152647Z
LAST-MODIFIED:20200824T153930Z
UID:3796-1598227200-1598659199@carb-x.org
SUMMARY:BIOCOM 4th AMR Conference: Novel Antimicrobials and AMR Diagnostics
DESCRIPTION:This year’s digital AMR Conference will be an international forum to discuss AMR in the context of COVID-19 and beyond. \nCARB-X speakers include Kevin Outterson\, Executive Director\, Erin Duffy\, Chief of Research and Development\, and Betsy Wonderly Trainor\, Alliance Director. \nThe current global health crisis caused by COVID-19 shows more than ever the importance of infectious diseases expertise and the high need for further fighting against antimicrobial resistance (AMR). A cross-sectoral international dialogue with all stakeholders involved will be crucial to help implement innovative therapies and diagnostics in the clinical practice globally. \nTogether with our supporters – among others our major partner\, the BEAM Alliance – the AMR Conference will continue to provide a (virtual) platform for those debates bringing together stakeholders from industry\, SMEs\, start-ups\, academia\, clinics\, investors\, public institutions and policy. Within our digital AMR Conference Week in August\, we want to catch up discussing the challenges of bringing new antimicrobial treatments and diagnostics into the market and as a result\, help to establish a post-COVID policy roadmap on AMR. \nFive days of insights and networking for the global AMR community: Each conference day will cover a focus topic with selected LIVE sessions and high-level panels. Additionally\, you will be able to explore scientific poster presentations and participate in virtual 1:1 meetings throughout the whole week and to engage within our new digital AMR stakeholder platform which is currently being set up. \n\n\n\n\n\nClick here to view the programme.\nClick here to learn more.\nClick here to register.
URL:https://carb-x.org/event/biocom-4th-amr-conference-novel-antimicrobials-and-amr-diagnostics/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200825T073000
DTEND;TZID=America/New_York:20200825T090000
DTSTAMP:20260403T180936
CREATED:20200817T131922Z
LAST-MODIFIED:20200819T143135Z
UID:4251-1598340600-1598346000@carb-x.org
SUMMARY:BIOCOM 4th AMR Conference: Business models | The AMR company of the future – Which route to success
DESCRIPTION:Moderator: \n\nErin Duffy – Chief of Research & Development\, CARB-X\n\nSpeakers: \n\nJonathan Butcher – Head of Business Development\, BioVersys AG\nCherif Bousselham – Senior Vice President\, Head of Sales\, EMEA\, Accelerate Diagnostics Inc.\nJean-Pierre Paccaud – Director of Business Development and Corporate Strategy\, GARDP\nKenneth Bradley – Global Head\, Infectious Disease Discovery\, Roche
URL:https://carb-x.org/event/biocom-4th-amr-conference-business-models-the-amr-company-of-the-future-which-route-to-success/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200825T091500
DTEND;TZID=America/New_York:20200825T101500
DTSTAMP:20260403T180936
CREATED:20200817T131812Z
LAST-MODIFIED:20200819T143409Z
UID:4250-1598346900-1598350500@carb-x.org
SUMMARY:BIOCOM 4th AMR Conference: Business models in AMR | How to develop strategic decisions in a challenging and global AMR market
DESCRIPTION:Moderator:  \n\nGökhan Batur – CEO\, Polyphor Ltd\n\nSpeakers: \n\nPeter Beyer – Senior Advisor Department of Essential Medicines & Health Products\, WHO\nErin Duffy – Chief of Research & Development\, CARB-X\nHolger Zimmermann – CEO\, AiCuris
URL:https://carb-x.org/event/biocom-4th-amr-conference-sme-approach-how-to-develop-strategic-decisions-in-a-challenging-and-global-amr-market/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200825T103000
DTEND;TZID=America/New_York:20200825T114500
DTSTAMP:20260403T180936
CREATED:20200817T132110Z
LAST-MODIFIED:20200819T143706Z
UID:4254-1598351400-1598355900@carb-x.org
SUMMARY:BIOCOM 4th AMR Conference: AMR pull incentives | Will COVID-19 speed up or slow down implementation?
DESCRIPTION:Moderator:  \n\nKathy Talkington\, Director Health Programs\, Pew Charitable Trust\n\nSpeakers: \n\nColm Leonard – Clinical Advisor/Consultant\, NICE\nKevin Outterson – Professor of Law & Executive Director\, CARB-X\nElmar Nimmesgern – Secretariat Lead\, Global AMR R&D Hub\nDaniel Berman – Lead of the Global Health Team\, Longitude Prize / Nesta
URL:https://carb-x.org/event/biocom-4th-amr-conference-amr-pull-incentives-will-covid-19-speed-up-or-slow-down-implementation/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200827
DTEND;VALUE=DATE:20200829
DTSTAMP:20260403T180936
CREATED:20200819T141417Z
LAST-MODIFIED:20200824T153935Z
UID:4279-1598486400-1598659199@carb-x.org
SUMMARY:Bacteriophage Therapy Summit
DESCRIPTION:As the scientific community search for alternatives to broad spectrum antibiotics\, phage therapy has re-emerged as a viable solution to tackle the global health challenge of anti-microbial resistance. \nAs such\, the 2nd Bacteriophage Therapy Summit returns digitally as a dedicated platform for leaders in industry and academia to accelerate the discovery and translation of bacteriophage research into targeted therapeutics that demonstrate clinically significant results. \nWith a heavy translationally focused agenda including how to overcome bacterial resistance scaling-up manufacturing and showing clinical efficacy this is your opportunity to join your peers to strengthen your product development pipelines and forge collaborations to unlock the full potential of bacteriophage therapeutics. \nView the full event guide for further details on speakers\, content and how to join those who paving the way for bacteriophage-based therapeutics!
URL:https://carb-x.org/event/bacteriophage-therapy-summit-2/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200827T060000
DTEND;TZID=America/New_York:20200827T070000
DTSTAMP:20260403T180936
CREATED:20200817T132156Z
LAST-MODIFIED:20200824T153824Z
UID:4255-1598508000-1598511600@carb-x.org
SUMMARY:BIOCOM 4th AMR Conference: SME campus (Part II) | Focus on diagnostics
DESCRIPTION:Moderator: \n\nBetsy Wonderly Trainor\, Alliance Director\, CARB-X\n\nSpeakers: \n\nPeter Haug – CFO & Co-Founder\, Head of Business Development & Licensing\, Noscendo GmbH\nPiotr Gastrecki – CTO\, ScopeFluidics\nRosemarie Preyer – GenID GmbH
URL:https://carb-x.org/event/biocom-4th-amr-conference-sme-campus-part-ii-focus-on-diagnostics/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200909
DTEND;VALUE=DATE:20200911
DTSTAMP:20260403T180936
CREATED:20200819T141833Z
LAST-MODIFIED:20200820T183034Z
UID:4281-1599609600-1599782399@carb-x.org
SUMMARY:PACCARB: Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria
DESCRIPTION:The September PACCARB meeting\, held virtually\, will focus on welcoming eight new liaison members and on the impact of COVID-19 and its affect on antimicrobial resistance (AMR). Topics will include presentations on the COVID-19 mortality rate due to secondary acquired infections\, antibiotic stewardship practices during a pandemic\, disruptions in the agricultural industry due to COVID-19 and the intersection of AMR and emergency preparedness. \nThis virtual public meeting is hosted by HHS and is open to the public. It will be held via webcast.The meeting can be accessed through a live webcast on the day of the meeting. \nLive Webcast: www.hhs.gov/live\nClick here to learn more.
URL:https://carb-x.org/event/paccarb-presidential-advisory-council-on-combating-antibiotic-resistant-bacteria/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200917T140000
DTEND;TZID=America/New_York:20200917T153000
DTSTAMP:20260403T180936
CREATED:20200916T133131Z
LAST-MODIFIED:20200916T133131Z
UID:4337-1600351200-1600356600@carb-x.org
SUMMARY:Building\, Funding\, and Growing Successful Biotech Startups
DESCRIPTION:Speakers include Cameron Bess\, Project Officer\, Antibacterials Branch\, Division of CBRN Medical Countermeasures\, BARDA. \nTurning a good scientific idea into a successful biotech startup is a challenging journey.This panel will highlight several successful paths that scientists can take toward creating a successful biotech company. Learn what New York-area resources are available to turn your idea into a business and help you develop entrepreneurial skills. \nThe event will introduce funding and strategic programs available from IndieBio\, the Center for Biotechnology\, the National Institutes of Health (NIH)\, and the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). \nSpeakers include: \n\nAnton Xavier\, Assistant Director of Technology and Business Development at the Center for Biotechnology.\nPhuong Nguyen\, Commercialization Fellow at the Center for Biotechnology.\nStephen Chambers\, Managing Director of IndieBio in New York.\nMatthew McMahon\, Director of NIH’s Small Business Education and Entrepreneurial Development (SEED) Program.\nCameron Bess\, Project Officer\, Antibacterials Branch\, Division of CBRN Medical Countermeasures\, BARDA.\n\nTo learn more and register\, click here. 
URL:https://carb-x.org/event/building-funding-and-growing-successful-biotech-startups/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200919T090000
DTEND;TZID=America/New_York:20200919T100000
DTSTAMP:20260403T180936
CREATED:20200916T174934Z
LAST-MODIFIED:20200916T174934Z
UID:4347-1600506000-1600509600@carb-x.org
SUMMARY:Antimicrobial Resistance Fighter Coalition Webinar: Responding to difficult-to-treat infections: Role and responsibilities of governments\, researchers\, clinicians\, industry and patients
DESCRIPTION:AMR in the Light of COVID-19 – A Webinar Series\nEach of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series\, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world. \nAbout this Webinar:\nGovernments\, researchers\, and industry partners around the world have mobilized to develop diagnostics\, therapeutics\, and vaccines for COVID-19. The development of new recommendations and practices continue to be deployed to slow the spread of COVID-19. The burden of drug-resistant infections could surpass COVID-19. Drugs like antibiotics are a vital tool for modern medicine\, used to prevent and treat infections. As drug-resistant infections are becoming more common\, modern medicine as we know it is at risk and much like COVID-19\, it has the potential to overwhelm our healthcare structure. What changes are needed to reshape strategies for combatting antimicrobial resistance globally? \nTo learn more about the Antimicrobial Resistance Fighter Coalition\, click here.\nTo learn more about this webinar series\, click here.\nTo register for this webinar\, click here.
URL:https://carb-x.org/event/antimicrobial-resistance-fighter-coalition-webinar-responding-to-difficult-to-treat-infections-role-and-responsibilities-of-governments-researchers-clinicians-industry-and-patients/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200922T070000
DTEND;TZID=America/New_York:20200922T080000
DTSTAMP:20260403T180936
CREATED:20200908T153527Z
LAST-MODIFIED:20200908T153553Z
UID:4314-1600758000-1600761600@carb-x.org
SUMMARY:Chatham House Webinar: Creating a New Generation of Antibiotics
DESCRIPTION:Participants include Kevin Outterson\, Executive Director of CARB-X. \nThe world needs a new generation of antibiotics to address the rapid growth in antibiotic-resistant bacteria. The UK government’s 2014 Review on Antimicrobial Resistance estimated that such bacteria could result in the deaths of 10 million people a year by 2050 and an accumulated cost of up to $100 trillion to the global economy. Despite this urgent need\, there remain few new antibiotics in development due to a lack of commercial viability for pharmaceutical companies with a 2019 Chatham House report highlighting the lack of progress being made on critical recommendations to tackle antimicrobial resistance. \nThis event will discuss the urgency of the development of new antibiotics and recent efforts to address the funding gap. What is the significance of the rise of antibiotic-resistant bacteria? What are the challenges at the intersection of increasing demand for new antibiotics and their commercial viability? Does the recent announcement of a new fund from the pharmaceutical industry represent a major shift\, or just the beginning\, of what is needed? \nParticipants: \n\nThomas Cueni\, Director General\, IFPMA\nJim O’Neill\, Chair\, Chatham House\nKevin Outterson\, Associate Fellow\, Global Health Programme\, Chatham House\nLaura Piddock\, Professor of Microbiology; Deputy Director of the\nInstitute of Microbiology and Infection\, University of Birmingham\nChair: Emma Ross\, Senior Research Fellow\, Global Health Programme\, Chatham House\n\nTo learn more\, click here.
URL:https://carb-x.org/event/chatham-house-webinar-webinar-creating-a-new-generation-of-antibiotics/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200923
DTEND;VALUE=DATE:20200926
DTSTAMP:20260403T180936
CREATED:20200820T183607Z
LAST-MODIFIED:20200820T183720Z
UID:4292-1600819200-1601078399@carb-x.org
SUMMARY:ESCMID Conference on Coronavirus Disease (ECCVID)
DESCRIPTION:Speakers include Kevin Outterson\, Executive Director of CARB-X. \nThe ESCMID Conference on Coronavirus Disease (ECCVID) will take place online from Wednesday 23rd to Friday 25th September 2020 and will cover all aspects of COVID-19. ECCVID will feature a comprehensive scientific programme that will span a wide range of topics surrounding this emerging threat.  \nCOVID-19 is a major public health incident which has brought about significant challenges and uncertainties with respect to diagnostics\, therapeutics and infection prevention and control. We are learning continually about the new SARS-CoV-2 virus and an international scientific event that brings together the latest research and scientific evidence is very timely. ECCVID will offer excellent opportunities to showcase the latest findings\, share experiences and knowledge and demonstrate practical techniques and guidance.  \nInternationally renowned clinical microbiologists\, infectious diseases specialists and experts from related disciplines will present their work and latest findings on COVID-19\, during the event. \nClick here to learn more.\nClick here to view the programme.\nClick here to register. \n 
URL:https://carb-x.org/event/escmid-conference-on-coronavirus-disease-eccvid/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200924T090000
DTEND;TZID=America/New_York:20200924T100000
DTSTAMP:20260403T180936
CREATED:20200916T174543Z
LAST-MODIFIED:20200916T174543Z
UID:4344-1600938000-1600941600@carb-x.org
SUMMARY:Antimicrobial Resistance Fighter Coalition Webinar: The global movement of microorganisms: Tracking the spread of difficult-to-treat infections
DESCRIPTION:AMR in the Light of COVID-19 – A Webinar Series\nEach of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series\, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world. \nAbout this Webinar:\nTracking the spread of COVID-19 has been critical to the global public health response. This information allows hospitals to prepare for surges\, governments to deploy testing strategies\, and citizens to modify their behavior appropriately. But while information about COVID-19 is readily and publicly available\, the world still struggles to monitor and track the spread of drug resistant infections.How should global monitoring and data sharing evolve to combat antimicrobial resistance? \nTo learn more about the Antimicrobial Resistance Fighter Coalition\, click here.\nTo learn more about this webinar series\, click here.\nTo register for this webinar\, click here.
URL:https://carb-x.org/event/antimicrobial-resistance-fighter-coalition-webinar-the-global-movement-of-microorganisms-tracking-the-spread-of-difficult-to-treat-infections/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200924T093000
DTEND;TZID=America/New_York:20200924T113000
DTSTAMP:20260403T180936
CREATED:20200908T154818Z
LAST-MODIFIED:20200908T154944Z
UID:4319-1600939800-1600947000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Moving from preclinical to clinical-stage: Challenges and opportunities
DESCRIPTION:Speakers: \n\nValue of a pre-IND interaction with the US FDA during late lead optimization: Bugworks experience – Bala Subramanian\, Bugworks Research Inc.\nAmicidins: Building clinical and regulatory strategies for non-traditional products to prevent and treat life-threatening infections – Michael P. Bevilacqua\, Amicrobe\, Inc.\nDiscovery and development of microbiome therapeutics using reverse translation – Matthew Henn & Chris Ford\, Seres\nTherapeutics Development of a multi-component toxoid vaccine for S. aureus – Regulatory challenges and opportunities – M. Javad Aman & Catherine Bernard\, Integrated BioTherapeutics\nRegulatory challenges for RaPID/BSI – culture-free identification and characterization of bloodstream infections – David Steinmiller\, HelixBind Inc.\n\nModerator: Erin Duffy\, CARB-X \nThe presentation will be followed by a Q&A session. \nRegister now for this live webinar.
URL:https://carb-x.org/event/live-webinar-gardp-revive-moving-from-preclinical-to-clinical-stage-challenges-and-opportunities/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200928
DTEND;VALUE=DATE:20201002
DTSTAMP:20260403T180936
CREATED:20200819T142611Z
LAST-MODIFIED:20200924T151406Z
UID:4283-1601251200-1601596799@carb-x.org
SUMMARY:World Vaccine Congress
DESCRIPTION:CARB-X speakers include Nadia Cohen\, Alliance Manager. \nThe World Vaccine Congress is an award-winning series of conferences and an exhibition that has grown to become the largest and most established vaccine meeting of its kind across the globe. Due to the global pandemic\, we have made a decision to run the 2020 congress VIRTUALLY. To mobilize\, coordinate and align funding to enable the research needed to tackle this crisis and stop the outbreak\, and commit with our experts how you can learn mechanisms for continuing scientific interactions and collaborations\, now and beyond the congress.\n  \nClick here to view the agenda.\nClick here to learn more.\nClick here to register. \nNadia Cohen will be participating in the panel\, World Vaccine Congress: Success case study 2 – Partnering with a non-profit for the first toxoid based multivalent vaccine for MRSA\, on September 29 at 2:40 pm – 3:10 pm ET.
URL:https://carb-x.org/event/world-vaccine-congress/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200930T090000
DTEND;TZID=America/New_York:20200930T121500
DTSTAMP:20260403T180936
CREATED:20200908T153930Z
LAST-MODIFIED:20200924T134830Z
UID:4317-1601456400-1601468100@carb-x.org
SUMMARY:Longitude Prize Sprint Workshop: How to Attract Investment
DESCRIPTION:Recent CARB-X graduate\, Specific Diagnostics\, will be participating in this workshop. \nThis workshop will be a forum for start-up and SMEs developing diagnostic tests to: \n\nHear from successful entrepreneurs who have built diagnostic companies\, what do they think were their key factors for success?\nHear from venture capital investors about what they expect and need before making investments.\nMeet in small break-out sessions in which you will interact directly with other medtech startups who have built or are in midst of building their enterprises and share insights.\nParticipate in panel discussion where you can ask both medtech leaders and venture capital fund managers about the intricacies and nuances of dilutive fund raise.\n\nNote: this webinar is the second in the Longitude Prize Sprint series. \nMore details can be found on the Longitude Prize website here. Registration is limited\, if you have trouble registering please send an email to longitude.prize@nesta.org.uk \nTo view the agenda\, click here.\nTo register\, click here.
URL:https://carb-x.org/event/longitude-prize-sprint-workshop-how-to-attract-investment/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201002
DTEND;VALUE=DATE:20201003
DTSTAMP:20260403T180936
CREATED:20200824T155054Z
LAST-MODIFIED:20200924T135933Z
UID:4304-1601596800-1601683199@carb-x.org
SUMMARY:Boston Area Antimicrobial Resistance Network (BAARN) Meeting
DESCRIPTION:CARB-X speakers include Su Chiang\, Alliance Manager. \nThe 7th BAARN meeting will bring together the leading voices in academia and industry to addresss a defining global health crisis of our age: antibiotic resistant infection. \nThis year will be BAARN’s inaugural virtual meeting. We are using online platforms to present an amazing lineup of researchers and innovators\, accessible to anyone with an internet connection. The event will stream on YOUTUBE LIVE. Zoom and YouTube Live links will be sent upon registration. \nThis event is co-coordinated by the Harvard Microbial Sciences Initiative and the Harvard Infectious Disease Institute. \nTo learn more\, click here. \nTo register\, click here.
URL:https://carb-x.org/event/boston-area-antimicrobial-resistance-network-baarn-meeting/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201008
DTEND;VALUE=DATE:20201010
DTSTAMP:20260403T180936
CREATED:20200817T133102Z
LAST-MODIFIED:20200924T145717Z
UID:4270-1602115200-1602287999@carb-x.org
SUMMARY:World Antimicrobial Resistance Congress 2020
DESCRIPTION:Erin Duffy\, CARB-X Chief of R&D\, is the chairperson of the event as well as a participant in a number of panels.  Other participants from CARB-X include Kevin Outterson (Executive Director)\, Richard Alm (Therapeutic R&D Alliance Director)\, Ed Buurman (Prevention R&D Alliance Director) and Betsy Wonderly Trainor (Diagnostic R&D Alliance Director).\n\nThe 6th annual World Antimicrobial Resistance Congress will be held virtually October 8-9\, 2020. It will showcase more than 250 presentations\, including speakers from CARB-X funded companies\, Forge and Entasis. \nAnti-microbial resistance continues to grow as a critical healthcare crisis globally. The number of deaths attributed to this epidemic is exponentially increasing\, and most measures and policies to combat AMR are deemed insufficient.Since 2015\, the World Anti-Microbial Resistance Congress has been the go-to conference globally for all stakeholders in the AMR space to meet\, brainstorm ideas and formulate initiatives that can effectively tackle this pressing issue. \nIndustry leaders\, innovative technology and solution providers\, public authorities\, international organizations\, infectious disease clinicians\, pharmacists and microbiologists are some of the 1\,000+ attendees from over 50 countries who will gather virtually this October 2020 at the World Anti-Microbial Resistance Congress. \nIf you work in these key areas of AMR\, then you must attend the World Anti-Microbial Resistance Congress 2020! \n\nClick here for more information.\nClick here to register.
URL:https://carb-x.org/event/world-antimicrobial-resistance-congress-2020/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201015T090000
DTEND;TZID=America/New_York:20201015T100000
DTSTAMP:20260403T180936
CREATED:20200916T174706Z
LAST-MODIFIED:20200916T174706Z
UID:4345-1602752400-1602756000@carb-x.org
SUMMARY:Antimicrobial Resistance Fighter Coalition Webinar: Prevention is stronger than a cure
DESCRIPTION:AMR in the Light of COVID-19 – A Webinar Series\nEach of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series\, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world. \nAbout this Webinar:\nPreventing drug resistant infections reduces the use of antibiotics and improves patient outcomes. Infection control practices\, from simple hand-washing to global vaccination\, and the use of effective infection prevention measures are key tools to combat COVID-19 and AMR. How has the COVID-19 pandemic informed our infection prevention efforts for healthcare systems and individuals around the world? \nTo learn more about the Antimicrobial Resistance Fighter Coalition\, click here.\nTo learn more about this webinar series\, click here.\nTo register for this webinar\, click here.
URL:https://carb-x.org/event/antimicrobial-resistance-fighter-coalition-webinar-prevention-is-stronger-than-a-cure/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201019
DTEND;VALUE=DATE:20201022
DTSTAMP:20260403T180936
CREATED:20200924T150127Z
LAST-MODIFIED:20200924T150127Z
UID:4402-1603065600-1603324799@carb-x.org
SUMMARY:5th Microbiome Movement - Drug Development Summit 2020
DESCRIPTION:The study of the human microbiome remains one of the most exciting frontiers in modern medicine that if targeted correctly\, has the potential to benefit millions of patients suffering from numerous diseases. However\, the potential for effective medicines powered by the microbiome is matched by the unique challenges in developing them. \nThe Microbiome Movement – Drug Development Summit returns as the “must attend meeting for the translational microbiome community” to help cutting-edge pharmaceutical and academic researchers pursue the causal role of the human microbiome in disease to help deliver a new generation of targeted therapeutics\, biomarker and diagnostics that demonstrate consistent clinical outcomes and predictabe MoAs. \nSo whether you’re part of a microbiome-focused biotech\, a pharmaceutical organization assessing this exciting field\, or an academic researcher with breakthrough findings\, join the Microbiome Movement as we explore the global advances in translational microbiome research\, and meet like-minded peers who are continuing to understand the causal and therapeutic potential of the ‘second genome’. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/5th-microbiome-movement-drug-development-summit-2020/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201019T040500
DTEND;TZID=America/New_York:20201019T040500
DTSTAMP:20260403T180936
CREATED:20200916T173318Z
LAST-MODIFIED:20200924T150708Z
UID:4341-1603080300-1603080300@carb-x.org
SUMMARY:World Vaccine Congress Europe: Changing the paradigm and finding a sustainable way to tackle AMR - The need for alternatives to antibiotics
DESCRIPTION:CARB-X speakers include Ed Buurman\, Alliance Director. \nTopics covered include: \n\nHow big is the problem economically speaking?\nShould we phase out broad-spectrum antibiotics?\nProgrammatic & technical challenges\nWhat can vaccines bring?\n\nClick here to view the agenda.\nClick here to learn more.\nClick here to register.
URL:https://carb-x.org/event/world-vaccine-congress-europe-changing-the-paradigm-and-finding-a-sustainable-way-to-tackle-amr-the-need-for-alternatives-to-antibiotics/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201021
DTEND;VALUE=DATE:20201026
DTSTAMP:20260403T180936
CREATED:20200908T155407Z
LAST-MODIFIED:20200908T160006Z
UID:4321-1603238400-1603670399@carb-x.org
SUMMARY:IDWeek 2020
DESCRIPTION:To learn more\, click here.\nTo view the program\, click here.\nTo register\, click here.
URL:https://carb-x.org/event/idweek-2020/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201026
DTEND;VALUE=DATE:20201030
DTSTAMP:20260403T180936
CREATED:20200908T155855Z
LAST-MODIFIED:20200908T161523Z
UID:4323-1603670400-1604015999@carb-x.org
SUMMARY:38th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2020)
DESCRIPTION:The 38th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID 2020) will be held on 26-29 October 2020 as a fully virtual meeting. \nThe organization of the meeting is a joint effort of ESPID members from the Netherlands. The ESPID forms the basis for investigators interested in infectious diseases in children and infection prevention in childhood. The main intent of the meeting is to bring together the most prominent researchers in and relevant to the field of paediatric infectious diseases and immunology. The meeting will provide an opportunity to exchange knowledge and generate new ideas in a relaxed\, smart albeit casual atmosphere. \nTo learn more\, click here.\nTo view the program\, click here.\nTo register\, click here.
URL:https://carb-x.org/event/38th-annual-meeting-of-the-european-society-for-paediatric-infectious-diseases-espid-2020/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201027
DTEND;VALUE=DATE:20201028
DTSTAMP:20260403T180936
CREATED:20200908T160156Z
LAST-MODIFIED:20201020T143659Z
UID:4326-1603756800-1603843199@carb-x.org
SUMMARY:BARDA Industry Day
DESCRIPTION:BARDA Industry Day is the annual meeting held to increase potential partner’s awareness of U.S. Government medical countermeasure priorities\, interact with BARDA and ASPR staff\, and network with public and private sector colleagues working in the Health Security space. This year\,  BARDA Industry Day 2020 will be virtual and will feature one day of exciting speakers\, breakout sessions\, and valuable networking opportunities!  The primary mission of BARDA’s industry day is to advance innovation and development of medical countermeasures\, bring together potential collaborators from across organizations\, share our accomplishments among our stakeholders\, and provide BARDA’s vision for the upcoming year’s priorities. \nBARDA\, through the CARB-X and Drive programs\, is supporting a networks of wrap-around-service-oriented accelerators that can be leveraged to prepare partners for donor funding. The hope is to fill and maintain a pipeline of partners ready and able to apply for advanced research support while bolstering the market of life-saving countermeasures. DRIVE and CARB-X will organize a panel of BARDA supported accelerators who will describe how “wrap-around services” have actually lead to better products (fitting the BID theme of ‘responding together’. At the end of the panel\, we will moderate a Q&A with audience members. Promotional material from other accelerators will be made available digitally for audience members. \nTo learn more\, click here.
URL:https://carb-x.org/event/barda-industry-day-2/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201028T040000
DTEND;TZID=America/New_York:20201028T053000
DTSTAMP:20260403T180936
CREATED:20201026T142510Z
LAST-MODIFIED:20201026T142557Z
UID:4512-1603857600-1603863000@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Developing antibiotics for children – medical need and regulatory challenges
DESCRIPTION:Speakers: \nPhoebe Williams\, Sydney Children’s Hospital and University of Sydney (Australia)\, will discuss: \n\nStatus quo – what antibiotics do we have (left) for children and babies\nWhere is the biggest medical need?\nChallenges of clinical trials in children – the clinicians perspective\nWhat impact will new drugs have in day-to-day practice and how does this depend on the setting (e.g. LMICs vs. high-income; community vs. hospital)?\n\nIrja Lutsar\, University of Tartu (Estonia)\, will discuss: \n\nClinical development of antibiotics for children; incl. new formulations of existing antibiotics including general regulatory requirements\nBrief overview of the type of data required for a new antibiotic for paediatric use; i.e. PK and other data\nChallenges of clinical trials in children and babies – the drug developers/regulatory perspective\n\nModerator: Sally Ellis (GARDP)  \nThe presentations will be followed by a Q&A session. \nTo learn more\, click here. 
URL:https://carb-x.org/event/live-webinar-gardp-revive-saving-childrens-lives-treating-neonatal-sepsis/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20201029T160000
DTEND;TZID=Europe/Paris:20201029T180000
DTSTAMP:20260403T180936
CREATED:20201013T195519Z
LAST-MODIFIED:20201013T195519Z
UID:4453-1603987200-1603994400@carb-x.org
SUMMARY:Interdisciplinary Course on Antibiotics and Resistance (ICARe) Webinar:
DESCRIPTION:Panelists include Erin Duffy\, CARB-X Chief of R&D \nPlease join us for a special ICARe webinar in light of the course’s 5th anniversary.  This two-hour event\, hosted by ICARe director Patrice Courvalin (Institut Pasteur\, France)\, will feature four 20-minute presentations from leading experts in antimicrobial resistance and antibiotic discovery research. Presentations will follow with a 30-minute panel discussion. \nThe webinar schedule is as follows: \n\n4:00: Patrice Courvalin (Institut Pasteur\, France) – Introduction\n4:05: Helen Boucher (Tufts Medical Center\, USA) – “Syndemics of AMR and COVID”\n4:25: Gerry Wright (McMaster University\, Canada) – “What’s new in antibiotic resistance?”\n4:45: Erin Duffy (CARB-X\, USA) – “Innovation in antibiotic discovery”\n5:05: John Rex (F2G\, UK)- “Prospects and remaining challenges in antibiotic development”\n5:25: Panel Discussion\n5:55: Patrice Courvalin (Institut Pasteur\, France) – Closing Remarks\n\nTo learn more\, click here.\nTo register\, click here.   \nAfter registering\, you will receive a confirmation email containing information about joining the webinar. Please note that the webinar start time is in Paris Time.​
URL:https://carb-x.org/event/interdisciplinary-course-on-antibiotics-and-resistance-icare-webinar/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201105T090000
DTEND;TZID=America/New_York:20201105T100000
DTSTAMP:20260403T180936
CREATED:20200916T174813Z
LAST-MODIFIED:20201013T200205Z
UID:4346-1604566800-1604570400@carb-x.org
SUMMARY:Antimicrobial Resistance Fighter Coalition Webinar: Aiming in the dark: what happens when disease spreads without diagnosis
DESCRIPTION:Panelists include Erin Duffy\, CARB-X Chief of R&D \nAMR in the Light of COVID-19 – A Webinar Series\nEach of us is now living in a world with a nearly untreatable virus – but COVID-19 is not the only threat that we are facing. Many bacterial and fungal infections that were previously considered treatable are no longer responding to the drugs designed to kill them. COVID-19 foreshadows a grim future if we do not mobilize a global response to the growing threat of antimicrobial resistance (AMR). Through a four-part series\, global experts will discuss how the COVID-19 pandemic could reshape strategies for combating antimicrobial resistance around the world. \nAbout this Webinar:\nThe pandemic has demonstrated the critical role of diagnostic testing to steer our public health response. It has been shown that diagnostic testing for bacterial and fungal infections results in improved use of antibiotics and antibiotic stewardship. But whereas testing for COVID-19 has benefited from innovation and rapid uptake\, testing for drug resistant infections remains underutilized. How can we improve the effective use of diagnostics\, globally\, for the diagnosis of bacterial and viral infections? \nTo learn more about the Antimicrobial Resistance Fighter Coalition\, click here.\nTo learn more about this webinar series\, click here.\nTo register for this webinar\, click here.
URL:https://carb-x.org/event/antimicrobial-resistance-fighter-coalition-webinar-aiming-in-the-dark-what-happens-when-disease-spreads-without-diagnosis/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201116
DTEND;VALUE=DATE:20201117
DTSTAMP:20260403T180936
CREATED:20201013T201730Z
LAST-MODIFIED:20201013T201930Z
UID:4460-1605484800-1605571199@carb-x.org
SUMMARY:FDA Public Workshop: Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs
DESCRIPTION:The Food and Drug Administration (FDA\, the Agency\, or we) is hosting a virtual public meeting entitled “Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs.” The purpose of the meeting is to obtain early input from the public on a potential revised approach for considering the human medical importance of antimicrobial new animal drugs when assessing and managing the antimicrobial resistance risks associated with the use of antimicrobial drugs in animals. The Agency is seeking public input on a potential revised process for ranking antimicrobials according to their relative importance in human medicine\, on the potential criteria for their ranking\, and on the resulting ranked list of antimicrobial drugs. A concept paper describing this potential revised process will be made available for discussion at the public meeting. \nClick here to learn more.\nClick here for the concept paper posted in advance of the meeting.
URL:https://carb-x.org/event/fda-public-workshop-potential-approach-for-ranking-of-antimicrobial-drugs-according-to-their-importance-in-human-medicine-a-risk-management-tool-for-antimicrobial-new-animal-drugs/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201117T100000
DTEND;TZID=America/New_York:20201117T110000
DTSTAMP:20260403T180936
CREATED:20201104T141806Z
LAST-MODIFIED:20201110T151145Z
UID:4546-1605607200-1605610800@carb-x.org
SUMMARY:CARB-X WEBINAR: Tackling Drug-resistant Bacteria: Exciting Science in the CARB-X Portfolio - Vedanta\, Eligo\, Peptilogics
DESCRIPTION:Join us Tuesday\, November 17\, at 10 AM – 11 AM ET for an update on CARB-X\, and an insider’s look at 3 innovative programs supported by CARB-X \nCARB-X is hosting this special webinar to showcase some of the exciting science in the CARB-X portfolio and the progress CARB-X is making supporting the development of innovative therapeutics\, preventatives and rapid diagnostics to address antibiotic-resistant bacteria. \nThe webinar will be moderated by Kevin Outterson\, Executive Director of CARB-X\, and will feature \n\nErin Duffy\, CARB-X R&D Chief\, on portfolio priorities and progress\nXavier Duportet\, Co-Founder and CEO of Eligo Bioscience\, on Eligo’s innovative CRISPR-based therapeutics derived from bacteriophages to prevent and treat antibiotic-resistant infections in transplant patients\nJonathan Steckbeck\, Founder and CEO of Peptilogics\, on the development of their first-in-class antibiotic peptide for the treatment of prosthetic joint infections which recently was granted Orphan Drug Designation by the US Food and Drug Administration\nBernat Olle\, Co-Founder and CEO of Vedanta Biosciences\, on Vedanta’s microbiome program\, including VE707\, an oral therapeutic designed to restore a patient’s healthy microbiota to that it can fight multidrug-resistant bacteria\, and VE303\, which has recently become the first CARB-X-funded therapeutic to go on to secure BARDA support for late-stage development\, and is also the first-ever BARDA award for research and development of a live bio-therapeutic product.\n\nA virtual Q&A will also be held. \nCLICK HERE TO REGISTER TODAY:\nOnce you register\, you will receive a confirmation and will be able to download an invitation to your calendar.
URL:https://carb-x.org/event/carb-x-webinar-tackling-drug-resistant-bacteria-exciting-science-in-the-carb-x-portfolio/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201117T110000
DTEND;TZID=America/New_York:20201117T123000
DTSTAMP:20260403T180936
CREATED:20201026T143033Z
LAST-MODIFIED:20201026T143155Z
UID:4511-1605610800-1605616200@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)
DESCRIPTION:Speakers: \n\nJames J. Collins\, Termeer Professor of Medical Engineering & Science Professor\, Broad Institute of MIT and Harvard (USA)\nCesar de la Fuente\, Presidential Assistant Professor\, University of Pennsylvania (USA)\nHenriette Willems\, Senior Research Associate\, The ALBORADA Drug Discovery Institute\, University of Cambridge\, (UK)\nFredrik Svensson\, Senior Research Associate\, UCL Drug Discovery Institute\, London\, (UK)\n\nModerator:  \n\nLaura Piddock\, Director of Scientific Affairs\, GARDP\n\nIn this webinar\, the speakers will give an overview of their work on the discovery of antibiotics through the use of artificial intelligence. The session will include the following presentations: \n\nDeep learning approaches to antibiotic discovery – James J. Collins\nAntibiotic discovery by means of computers – Cesar de la Fuente\nComputational Chemistry on a Budget – Henriette Willems & Fredrik Svensson\n\nTo learn more\, click here. 
URL:https://carb-x.org/event/live-webinar-gardp-revive-discovery-of-new-antibacterials-using-artificial-intelligence-computational-chemoinformatics/
LOCATION:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201118
DTEND;VALUE=DATE:20201125
DTSTAMP:20260403T180936
CREATED:20201110T184941Z
LAST-MODIFIED:20201110T184941Z
UID:4564-1605657600-1606262399@carb-x.org
SUMMARY:World Antimicrobial Awareness Week 2020
DESCRIPTION:The theme for World Antimicrobial Awareness Week 2020 for the human health sector is “United to preserve antimicrobials.” \nEvery year\, World Antimicrobial Awareness Week aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices among the general public\, health workers and policy makers to stop the further emergence and spread of drug-resistant infections. \nWAAW has expanded its scope to address not just antibiotics\, but all antimicrobials\, including antiviral\, antifungal and antiparasitic medicines. This exciting decision came on the strong recommendation of the antimicrobial resistance (AMR) community. In the midst of a global pandemic\, stakeholders came together virtually to discuss the challenges and opportunities for the WAAW campaign and awareness of Antimicrobial Resistance (AMR) more generally. The overarching message was that all sectors needed to unite to change behaviours and that the campaign needed to broaden its scope from antibiotics\, to include all antimicrobials. \nFor the first time ever\, we are also celebrating WAAW at a time when traditional methods of campaigning are not possible. We are challenged by new rules of social distancing\, limitations on public gatherings\, and physical isolation. As with the global virtual consultation in May 2020\, however\, the AMR community has shown its commitment\, resilience and eagerness to celebrate\, unite\, and build awareness around an issue that is becoming one of the most significant challenges to our global health and development objectives. Over the 7 days of WAAW 2020\, events will be held virtually in all regions of the world\, by governments\, academics\, students\, health care workers\, NGOs and all those interested and passionate about combating AMR. \nTo learn more\, click here.
URL:https://carb-x.org/event/world-antimicrobial-awareness-week-2020/
LOCATION:Virtual Event\, 765 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
END:VEVENT
END:VCALENDAR